Mercury toxicity and antioxidants: Part I: Role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity

Alternative Medicine Review

Volumn 7, Issue 6, 2002, Pages 456-471

  Patrick, Lyn ^a,b  

^a Bastyr University   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; COPPER; GLUTATHIONE; IRON; LEAD; MERCURY; METHYLMERCURY; OXIDOREDUCTASE; PLATINUM; PYRUVIC ACID; THIOCTIC ACID; THIOMERSAL;

ANTIOXIDANT ACTIVITY; CHELATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; ECOTOXICOLOGY; ENZYME ANALYSIS; FISH; FOOD CONTAMINATION; GERMANY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MERCURIALISM; METAL BINDING; NEUROLOGIC DISEASE; NEUROPROTECTION; OXIDATIVE STRESS; POLYNEUROPATHY; REVIEW;

ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CHELATING AGENTS; FOOD CONTAMINATION; GLUTATHIONE; HUMANS; KIDNEY; MERCURY; MERCURY POISONING; SUCCIMER; THIOCTIC ACID; TISSUE DISTRIBUTION; UNITHIOL;

EID: 0036925813     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Agency for Toxic Substances and Disease Registry (ATSDR). 2001 CERCLA Priority List of Hazardous Substances. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. www.atsdr.cdc.gov/clist.html
2. Ozuah PO. Mercury poisoning. Curr Probl Pediatr 2000;30:91-99.
3. Ferrara R, Mazzolai B, Lanzillotta E, et al. Temporal trends in gaseous mercury evasion from the Mediterranean seawaters. Sci Total Environ 2000;259:183-190.
4. Agency for Toxic Substances and Disease Registry (ATSDR). 1999 Toxicological Profile for Mercury. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. www.atsdr.cdc.gov/toxprofiles/tp46.html
5. Environmental Working Group. What Women Should Know About Mercury Contamination of Fish. Washington, DC: Environmental Working Group; 2001:1-4.
6. National Research Council. Toxicological Effects of Methylmercury. Washington, DC: National Academy Press; 2000:33-35.
7. Clarkson TW. The three modern faces of mercury. Environ Health Perspect 2002;110:11-23.
8. Yannai S, Berdicevsky I, Duek L. Transformations of inorganic mercury by Candida albicans and Saccharomyces cerevisiae. Appl Environ Microbiol 1991;57:245-247.
9. Tunnessen WW Jr, McMahon KJ, Baser M. Acrodynia: Exposure to mercury from fluorescent light bulbs. Pediatrics 1987;79:786-789.
10. Kojima S, Shimada H, Kiyozumi M. Comparative effects of chelating agents on distribution, excretion, and renal toxicity of inorganic mercury in rats. Res Commun Chem Pathol Pharmacol 1989;64:471-484.
11. Halsey NA. Limiting infant exposure to thimerosal in vaccines and other sources of mercury. JAMA 1999;282:1763-1766.
12. Cernichiari E, Brewer R, Myers GJ, et al. Monitoring methylmercury during pregnancy: Maternal hair predicts fetal brain exposure. Neurotoxicology 1995;16:705-710.
13. Alexander J, Aaseth J. Organ distribution and cellular uptake of methyl mercury in the rat as influenced by the intra- and extracellular glutathione concentration. Biochem Pharmacol 1982;31:685-690.
14. Davis LE, Kornfield M, Mooney HS, et al. Methylmercury poisoning: Long-term clinical, radiological, toxicological and pathological studies of an affected family. Ann Neurol 1994;35:680-688.
15. Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995;91:645-655.
16. Salonen JT, Seppanen K, Lakka TA, et al. Mercury accumulation and accelerated progression of carotid atherosclerosis: A population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000;148:265-273.
17. Sorensen N, Murata K, Budtz-Jorgensen E, et al. Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology 1999;10:370-375.
18. National Research Council. Toxicological Effects of Methylmercury. Washington, DC: National Academy Press; 2000:31-70.
19. Yee S, Choi BH. Oxidative stress in neurotoxic effects of methylmercury poisoning. Neurotoxicology 1996:17:17-26.
20. National Research Council. Toxicological Effects of Methylmercury. Washington, DC: National Academy Press; 2000:54-55.
21. National Research Council. Toxicological Effects of Methylmercury. Washington, DC: National Academy Press; 2000:55-56.
22. Divine KK, Ayala-Fierro F, Barber DS, Carter DE. Glutathione, albumin, cysteine, and cysgly effects on toxicity and accumulation of mercuric chloride in LLC-PK1 cells. J Toxicol Environ Health A 1999;57:489-505.
23. Kerper LE, Mokrzan EM, Clarkson TW, Ballatori N. Methylmercury efflux from brain capillary endothelial cells is modulated by intracellular glutathione but not ATP. Toxicol Appl Pharmacol 1996;141:526-531.
24. Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev 2000;52:113-143.
25. Aschner M, Aschner JL. Mercury neurotoxicity: Mechanisms of blood-brain barrier transport. Neurosci Biobehav Rev 1990;14:169-176.
26. Sen C. Nutritional biochemistry of cellular glutathione. J Nutr Biochem 1997;8:660-672.
27. Lee YW, Ha MS, Kim YK. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res 2001;26:1187-1193.
28. Queiroz ML, Pena SC, Salles TS, et al. Abnormal antioxidant system in erythrocytes of mercury-exposed workers. Hum Exp Toxicol 1998;17:225-230.
29. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17:888-895.
30. Kromidas L, Trombetta LD, Jamall IS. The protective effects of glutathione against methylmercury cytotoxicity. Toxicol Lett 1990;51:67-80.
31. Ballatori N, Clarkson TW. Dependence of biliary secretion of inorganic mercury on the biliary transport of glutathione. Biochem Pharmacol 1984;33:1093-1098.
32. Ballatori N, Clarkson TW. Biliary transport of glutathione and methylmercury. Am J Physiol 1983;244:G435-G441.
33. Ballatori N, Clarkson TW. Biliary secretion of glutathione and of glutathione-metal complexes. Fundam Appl Toxicol 1985;5:816-831.
34. Magos L, Clarkson TW, Allen J. The interrelationship between non-protein bound thiols and the biliary excretion of methylmercury. Biochem Pharmacol 1978;27:2203-2208.
35. Gregus Z, Varga F. Role of glutathione and hepatic glutathione S-transferase in the biliary excretion of methyl mercury, cadmium, and zinc: A study with enzyme inducers and glutathione depletors. Acta Pharmacol Toxicol (Copenh) 1985:56:398-403.
36. Tiffany-Castiglion E, Qian Y. Astroglia as metal depots: Molecular mechanisms for metal accumulation, storage and release. Neurotoxicology 2001;22:577-592.
37. Cookson MR, Pentreath VW. Protective roles of glutathione in the toxicity of mercury and cadmium compounds to C6 glioma cells. Toxicol In Vitro 1996;10:257-264.
38. Fujiyama J, Hirayama K, Yasutake A. Mechanism of methylmercury efflux from cultured astrocytes. Biochem Pharmacol 1994;47:1525-1530.
39. Endo T, Sakata M. Effects of sulfhydryl compounds on the accumulation, removal and cytotoxicity of inorganic mercury by primary cultures of rat renal cortical epithelial cells. Pharmacol Toxicol 1995;76:190-195.
40. Lash LH, Putt DA, Zalups RK. Influence of exogenous thiols on inorganic mercury-induced injury in renal proximal and distal tubular cells from normal and uninephrectomized rats. J Pharmacol Exp Ther 1999;291:492-502.
41. Miura K, Clarkson TW. Reduced methylmercury accumulation in a methylmercury-resistant rat pheochromocytoma PC12 cell line. Toxicol Appl Pharmacol 1993;118:39-45.
42. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997;29:315-331.
43. Jones MM, Cherian MG. The search for chelate antagonists for chronic cadmium intoxication. Toxicology 1990;62:1-25.
44. Peinado J, Sies H, Akerboom TP. Hepatic lipoate uptake. Arch Biochem Biophys 1989;273:389-395.
45. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Rad Biol Med 1995;19:227-250.
46. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-378.
47. Nickander KK, McPhee BR, Low PA, Tritschler H. alpha-Lipoic acid: Antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996;21:631-639.
48. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-1301.
49. Bustamante J, Lodge JK, Marcocci L, et al. alpha-Lipoic acid in liver metabolism and disease. Free Radic Biol Med 1998;24:1023-1039.
50. Han D, Handelman G, Marcocci L, et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 1997;6:321-338.
51. Khanna S, Atalay M, Laaksonen DE, et al. alpha-Lipoic acid supplementation: Tissue glutathione homeostasis at rest and after exercise. J Appl Physiol 1999;86:1191-1196.
52. Han D, Tritschler HJ, Packer L. alpha-Lipoic acid increases intracellular glutathione in a human T-lymphocyte Jurkat cell line. Biochem Biophys Res Commun 1995;207:258-264.
53. Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung 1992;42:829-831.
54. Moini H, Packer L, Saris NE. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 2002;182:84-90.
55. Lynch MA. Lipoic acid confers protection against oxidative injury in non-neuronal and neuronal tissue. Nutr Neurosci 2001;4:419-438.
56. Ou P, Tritschler HJ, Wolff SP. Thioctic (lipoic) acid: A therapeutic metal-chelating antioxidant? Biochem Pharmacol 1995;50:123-126.
57. + by dihydrolipoic acid prevents human low density lipoprotein peroxidation. Free Radic Biol Med 1998;25:287-297.
58. de Costa VS, Morbus DA. Wilson's disease and the possible therapeutic role of alpha-lipoic acid. Arzneimittelforschung 1970;20:1210-1213.
59. Bonomi F, Cerioli A, Pagani S. Molecular aspects of the removal of ferritin-bound iron by DL-dihydrolipoate. Biochim Biophys Acta 1989;994:180-186.
60. Somani SM, Husain K, Whitworth C, et al. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. Pharmacol Toxicol 2000;86:234-241.
61. Gurer H, Ozgunes H, Oztezcan S, Ercal N. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic Biol Med 1999;27:75-81.
62. Fowler BA. General subcellular effects of lead, mercury, cadmium, and arsenic. Environ Health Perspect 1978;22:37-41.
63. + toxicity in isolated hepatocytes. Biochim Biophys Acta 1990;1052:386-391.
64. Muller L. Protective effects of d1-alpha-lipoic acid on cadmium-induced deterioration of rat hepatocytes. Toxicology 1989;58:175-185.
65. Sumathi R, Baskaran G, Varalakshmi P. Relationship between glutathione and d1 alpha-lipoic acid against cadmium-induced hepatotoxicity. Jpn J Med Sci Biol 1996;49:39-48.
66. Grunert RR. The effect of d1-alpha-lipoic acid on heavy-metal intoxication in mice and dogs. Arch Biochem Biophys 1960;86:190-194.
67. Gregus Z, Stein AF, Varga F, Klassen CD. Effect of lipoic acid on biliary excretion of glutathione and metals. Toxicol Appl Pharmacol 1992;114:88-96.
68. Anuradha B, Varalakshmi P. Protective role of d1-alpha-lipoic acid against mercury-induced neural lipid peroxidation. Pharmacol Res 1999;39:67-80.
69. Keith RL, Setiarahardjo I, Fernando Q, et al. Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. Toxicology 1997;116:67-75.
70. Aposhian HV, Maiorino RM, Rivera M, et al. Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol 1992;30:505-528.
71. Hibberd AR, Howard MA, Hunnisett AG. Mercury from dental amalgam fillings: Studies on oral chelating agents for assessing and reducing mercury burdens in humans. J Nutr Environ Med 1998;8:219-231.
72. Gonzalez-Ramirez D, Zuniga-Charles M, Narro-Juarez A, et al. DMPS (2,3-dimercaptopropane-1-sulfonate, dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J Pharmacol Exp Ther 1998;287:8-12.
73. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995;97:23-38.
74. Forman J, Moline J, Cernichiari E, et al. A cluster of pediatric metallic mercury exposure cases treated with meso-2,3-dimercaptosuccinic acid (DMSA). Environ Health Perspect 2000;108:575-577.
75. Goyer RA, Cherian MG, Jones MM, Reigart JR. Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals. Environ Health Perspect 1995;103:1048-1052.
76. Zalups RK, Parks LD, Cannon VT, Barfuss DW. Mechanisms of action of 2,3-dimercaptopropane-1-sulfonate and the transport, disposition, and toxicity of inorganic mercury in isolated perfused segments of rabbit proximal tubules. Mol Pharmacol 1998;54:353-363.
77. Aposhian HV. DMSA and DMPS - Water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol 1983;23:193-215.
78. Cherian MG, Miles EF, Clarkson TW, Cox C. Estimation of mercury burdens in rats by chelation with dimercaptopropane sulphonate. J Pharmacol Exp Ther 1988;245:479-484.